683 CAPITAL MANAGEMENT LLC
Q3 2026 Form 13-F
NEW YORK, NEW YORK
CIK 0001404574
· CRD 156181
· SEC-registered investment adviser
Consolidated report · includes
1 manager
since Q2 2013
$2.4B Reported Value Total
683 CAPITAL MANAGEMENT, LLC reports 2 total accounts under management (AUM). There are 2 discretionary accounts valued at $2,436,885,197, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered
Discretionary Manager
Private funds (Form ADV)
2 funds
· $2.4B gross asset value
Hedge Fund: $2.4B
Source: Form ADV filed 2026-03-30
Reported value
$2.4B
Quarter over quarter
-3.9%
Holdings
122
Top-10 concentration
54.6%
Filing Structure
Reports holdings for
- 683 Capital Partners LP · File #028-14774 · since Q2 2013
Key People
Form ADV owners & control persons
John Andrew Levin
MANAGING MEMBER
Ari Jonathan Zweiman
MANAGING MEMBER
Joseph S Patt
PARTNER
Filing Navigation
Coverage begins with the second quarter of 2013. Earlier quarters are not shown while their accuracy is being verified.
13F Metrics
Loading 13F Metrics
Q3 2026 13F record
Q3 2026 13F filing summary
| Period of report | September 30, 2026 |
|---|---|
| Filed | November 16, 2026 |
| Form | 13F-HR |
| Reported value | $2.4B |
| Positions | 122 |
| Change in reported value | +18.2% |
| New positions | 12 |
| Exited positions | 15 |
| Position turnover | 19.7% |
| Top-10 concentration | 54.6% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 16, 2026
|
122 | $2.4B |
|
Q2 2026 13F
Filed Aug 14, 2026
|
125 | $2.0B |
|
Q1 2026 13F
Filed May 15, 2026
|
204 | $1.9B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
201 | $2.3B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
113 | $1.9B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
111 | $1.5B |
|
Q1 2025 13F
Filed May 15, 2025
|
114 | $1.4B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
205 | $1.6B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
124 | $1.3B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
124 | $1.3B |
|
Q1 2024 13F
Filed May 15, 2024
|
118 | $1.4B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
236 | $1.2B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
127 | $1.3B |
|
Q2 2023 13F
Filed Aug 14, 2023
|
135 | $1.4B |
|
Q1 2023 13F
Filed May 15, 2023
|
263 | $1.3B |
|
Q4 2022 13F
Filed Feb 14, 2023
|
290 | $1.2B |
|
Q3 2022 13F
Filed Nov 14, 2022
|
231 | $1.3B |
|
Q2 2022 13F
Filed Aug 15, 2022
|
260 | $1.4B |
|
Q1 2022 13F
Filed May 16, 2022
|
342 | $1.9B |
|
Q4 2021 13F
Filed Feb 14, 2022
|
327 | $2.7B |
34 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q3 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | PLTR P PALANTIR TECHNOLOGIES INC | $454.3M | 18.88% |
| 2 | XBI P SPDR SERIES TRUST | $219.2M | 9.11% |
| 3 | LLY P ELI LILLY & CO | $168.9M | 7.02% |
| 4 | NVDA P NVIDIA CORPORATION | $104.1M | 4.33% |
| 5 | ARKG P ARK ETF TR | $92.2M | 3.83% |
| 6 | COF CAPITAL ONE FINL CORP | $70.5M | 2.93% |
| 7 | ABBV P ABBVIE INC | $64.1M | 2.66% |
| 8 | CVNA CARVANA CO | $49.7M | 2.07% |
| 9 | MDGL P MADRIGAL PHARMACEUTICALS INC | $45.4M | 1.88% |
| 10 | BDX BECTON DICKINSON & CO | $44.8M | 1.86% |
| 11 | KSPI KASPI KZ JSC | $44.2M | 1.84% |
| 12 | META META PLATFORMS INC | $40.6M | 1.69% |
| 13 | ANAB ANAPTYSBIO INC | $37.2M | 1.55% |
| 14 | PTGX PROTAGONIST THERAPEUTICS INC | $35.9M | 1.49% |
| 15 | MRNA P MODERNA INC | $34.9M | 1.45% |
| 16 | AMLX AMYLYX PHARMACEUTICALS INC | $33.5M | 1.39% |
| 17 | PRAX P PRAXIS PRECISION MEDICINES I | $32.2M | 1.34% |
| 18 | MOH MOLINA HEALTHCARE INC | $31.2M | 1.3% |
| 19 | IOVA P IOVANCE BIOTHERAPEUTICS INC | $30.2M | 1.26% |
| 20 | ALNY P ALNYLAM PHARMACEUTICALS INC | $26.5M | 1.1% |
Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.